Anti-KDM1A/ LSD/ AOF2 functional antibody
Anti-KDM1A/ LSD/ AOF2 functional antibody for cell culture, ELISA & in-vivo assay
Go to LSD/KDM1A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T16739-Ab-1/ GM-Tg-hg-T16739-Ab-2 | Anti-Human LSD/KDM1A monoclonal antibody | Human |
GM-Tg-rg-T16739-Ab-1/ GM-Tg-rg-T16739-Ab-2 | Anti-Rat LSD/KDM1A monoclonal antibody | Rat |
GM-Tg-mg-T16739-Ab-1/ GM-Tg-mg-T16739-Ab-2 | Anti-Mouse LSD/KDM1A monoclonal antibody | Mouse |
GM-Tg-cynog-T16739-Ab-1/ GM-Tg-cynog-T16739-Ab-2 | Anti-Cynomolgus/ Rhesus macaque LSD/KDM1A monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T16739-Ab-1/ GM-Tg-felg-T16739-Ab-2 | Anti-Feline LSD/KDM1A monoclonal antibody | Feline |
GM-Tg-cang-T16739-Ab-1/ GM-Tg-cang-T16739-Ab-2 | Anti-Canine LSD/KDM1A monoclonal antibody | Canine |
GM-Tg-bovg-T16739-Ab-1/ GM-Tg-bovg-T16739-Ab-2 | Anti-Bovine LSD/KDM1A monoclonal antibody | Bovine |
GM-Tg-equg-T16739-Ab-1/ GM-Tg-equg-T16739-Ab-2 | Anti-Equine LSD/KDM1A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T16739-Ab-1/ GM-Tg-hg-T16739-Ab-2; GM-Tg-rg-T16739-Ab-1/ GM-Tg-rg-T16739-Ab-2; GM-Tg-mg-T16739-Ab-1/ GM-Tg-mg-T16739-Ab-2; GM-Tg-cynog-T16739-Ab-1/ GM-Tg-cynog-T16739-Ab-2; GM-Tg-felg-T16739-Ab-1/ GM-Tg-felg-T16739-Ab-2; GM-Tg-cang-T16739-Ab-1/ GM-Tg-cang-T16739-Ab-2; GM-Tg-bovg-T16739-Ab-1/ GM-Tg-bovg-T16739-Ab-2; GM-Tg-equg-T16739-Ab-1/ GM-Tg-equg-T16739-Ab-2 |
Products Name | Anti-LSD/KDM1A monoclonal antibody |
Format | mab |
Target Name | LSD |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-LSD benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T16739-Ag-1 | Recombinant multi-species KDM1A/ LSD/ AOF2 protein |
ORF Viral Vector | vGMLP001675 | human KDM1A Lentivirus particle |
ORF Viral Vector | pGMLP001675 | human KDM1A Lentivirus plasmid |
Target information
Target ID | GM-T16739 |
Target Name | LSD |
Gene ID | 23028,99982,500569,718609,478193,101096583,532997,100071646 |
Gene Symbol and Synonyms | 1810043O07Rik,AOF2,BHC110,CPRF,D4Ertd478e,KDM1,KDM1A,LSD1,mKIAA0601,RGD1562975 |
Uniprot Accession | O60341 |
Uniprot Entry Name | KDM1A_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Therapeutics Target |
Disease | Cancer |
Gene Ensembl | ENSG00000004487 |
Target Classification | Tumor-associated antigen (TAA) |
The target: LSD, gene name: KDM1A, also named as AOF2, BHC110, CPRF, KDM1, LSD1. This gene encodes a nuclear protein containing a SWIRM domain, a FAD-binding motif, and an amine oxidase domain. This protein is a component of several histone deacetylase complexes, though it silences genes by functioning as a histone demethylase. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2009].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.